Evidence map›Paper›PMID 39365782›Full record

ArticlePLOS global public health2024

Bio-efficacy of field aged novel class of long-lasting insecticidal nets, against pyrethroid-resistant malaria vectors in Tanzania: A series of experimental hut trials.

Jackline L Martin, Louisa A Messenger, Mark Rowland, Franklin W Mosha, Edmund Bernard, Monica Kisamo, Shaban Limbe, Patric Hape, Charles Thickstun, Crene Steven and 9 more

Abstract read
In one paragraph

Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Comparative malaria impact of chlorfenapyr-α-cypermethrin netsCurrent research in parasitology & vector-borne diseases · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jackline L MartinDepartment of Parasitology, Pan-African Malaria Vector Research Consortium, Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania.ORCID https://orcid.org/0000-0003-4629-8837
Louisa A MessengerDepartment of Disease Control, Faculty of Tropical Diseases, London School of Hygiene and Tropical, London, United Kingdom.
Mark RowlandDepartment of Disease Control, Faculty of Tropical Diseases, London School of Hygiene and Tropical, London, United Kingdom.
Franklin W MoshaDepartment of Parasitology, Pan-African Malaria Vector Research Consortium, Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania.
Edmund BernardDepartment of Parasitology, National Institute for Medical Research, National Institute for Medical Research- Mwanza Center, Mwanza, United Republic of Tanzania.
Monica KisamoDepartment of Parasitology, National Institute for Medical Research, National Institute for Medical Research- Mwanza Center, Mwanza, United Republic of Tanzania.
Shaban LimbeDepartment of Parasitology, National Institute for Medical Research, National Institute for Medical Research- Mwanza Center, Mwanza, United Republic of Tanzania.ORCID https://orcid.org/0009-0004-0401-815X
Patric HapeDepartment of Parasitology, National Institute for Medical Research, National Institute for Medical Research- Mwanza Center, Mwanza, United Republic of Tanzania.
Charles ThickstunSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Crene StevenDepartment of Parasitology, Pan-African Malaria Vector Research Consortium, Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania.ORCID https://orcid.org/0009-0007-3852-0051
Oliva MoshiDepartment of Parasitology, Pan-African Malaria Vector Research Consortium, Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania.
Boniface ShirimaDepartment of Parasitology, Pan-African Malaria Vector Research Consortium, Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania.
Nancy S MatowoDepartment of Disease Control, Faculty of Tropical Diseases, London School of Hygiene and Tropical, London, United Kingdom.ORCID https://orcid.org/0000-0002-2302-3796
Jacklin F MoshaDepartment of Parasitology, National Institute for Medical Research, National Institute for Medical Research- Mwanza Center, Mwanza, United Republic of Tanzania.
Dominic P DeeImperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-0087-3851
Thomas S ChurcherImperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-8442-0525
Manisha A KulkarniSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.ORCID https://orcid.org/0000-0002-5084-4960
Alphaxard ManjuranoDepartment of Parasitology, National Institute for Medical Research, National Institute for Medical Research- Mwanza Center, Mwanza, United Republic of Tanzania.
Natacha ProtopopoffDepartment of Disease Control, Faculty of Tropical Diseases, London School of Hygiene and Tropical, London, United Kingdom.ORCID https://orcid.org/0000-0001-6698-4936

Funding

Wellcome Trust
6 · The paper itself

Abstract

New classes of long-lasting insecticidal nets (LLINs), have been recommended by the World Health Organization (WHO) to control malaria vectors resistant to pyrethroid insecticides. This study was nested in a large-scale cluster-randomized controlled trial conducted (cRCT) in Tanzania. A series of experimental hut trials (EHTs) aimed to evaluate the bio-efficacy of trial LLINs on mosquito indicators most pertinent to malaria transmission over 3 years of use in the community in order to better understand the outcomes of the cRCT. The following field-collected LLINs were assessed: 1) Olyset Plus (combining piperonyl butoxide synergist and permethrin), 2) Interceptor G2 (chlorfenapyr and alpha-cypermethrin), 3) Royal Guard (pyriproxyfen and alpha-cypermethrin), 4) Interceptor (alpha-cypermethrin only) conducted in parallel with 5) a new Interceptor, and 6) an untreated net. Thirty nets of each type were withdrawn from the community at 12, 24, and 36 months after distribution and used for the EHTs. Pre-specified outcomes were 72-hour mortality for Interceptor G2, 24-hour mortality for Olyset Plus, and fertility based on egg development stage for Royal Guard. Overall, Interceptor G2 LLINs induced higher 72-hour mortality compared to standard LLINs of the same age up to12 months (44% vs 21%, OR: 3.5, 95% CI: 1.9-6.6, p-value < 0.001), and 24-hour mortality was only significantly higher in Olyset Plus when new (OR: 13.6, 95%CI: 4.4-41.3, p-value < 0.001) compared to standard LLINs but not at 12 months (17% vs 13%; OR: 2.1, 95% CI: 1.0-4.3; p-value = 0.112). A small, non-significant effect of pyriproxyfen on Anopheles fertility was observed for Royal Guard up to 12 months (75% vs 98%, OR: 1.1, 95% CI: 0.0-24.9, p-value = 0.951). There was no evidence of a difference in the main outcomes for any of the new classes of LLINs at 24 and 36 months compared to standard LLINs. Interceptor G2 LLINs showed superior bio-efficacy compared to standard LLINs only up to 12 months, and the effect of Olyset Plus was observed when new for all species and 12 months for An. gambiae s.l. only. The pyriproxyfen component of Royal Guard had a short and limited effect on fertility. The decrease in effectiveness of Olyset Plus and Royal Guard LLINs in the EHTs aligns with findings from the cRCT, whereas efficacy of Interceptor G2 lasted for a longer period in the cRCT compared to the EHT. Further investigations are needed to understand the complete scope of chlorfenapyr mode of action. Additional EHT in various contexts will help confirm the residual efficacy of the dual active ingredient LLINs and support the development of longer-lasting nets.

Identifiers

PMID39365782
PMCPMC11451999

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.